

BIOANALYTICAL VALIDATION OF ANTIMICROBIAL DRUGS IN RABBIT PLASMA USING REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY: A REVIEW

Dantinapalli V. L. Sagar^{*1}, Sanjay Saxena²

¹Research Scholar, Department of Chemistry, School of Basic and applied Sciences, Raffles University, Neemrana-301705, 0009-0007-3371-2791.

²Professor, Department of Chemistry, School of Basic and applied Sciences, Raffles University, Neemrana-301705.

Article Received on 15 Sept. 2026,
Article Revised on 05 Oct. 2026,
Article Published on 16 Oct. 2026,

<https://doi.org/10.5281/zenodo.23383992>

*Corresponding Author

Dantinapalli VL Sagar

Research Scholar, Department of
Chemistry, School of Basic and
Applied Sciences, Raffles
University, Neemrana-301705,
0009-0007-3371-2791.



How to cite this Article: Dantinapalli V. L. Sagar^{*1}, Sanjay Saxena². (2026). Bioanalytical Validation of Antimicrobial Drugs In Rabbit Plasma Using Reverse-Phase High-Performance Liquid Chromatography: A Review. World Journal of Pharmaceutical Research, 15(20), 453-463.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Bioanalytical method development and validation are essential for the reliable quantification of antimicrobial drugs in biological matrices and for generating dependable pharmacokinetic and toxicokinetic data. Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used for bioanalytical investigations because of its reproducibility, versatility, sensitivity, and suitability for quantitative analysis. Rabbit plasma is frequently employed in preclinical studies, although endogenous proteins, lipids, salts, and metabolites can interfere with chromatographic determination and therefore require appropriate sample preparation. This review discusses the principles involved in developing and validating RP-HPLC methods for the determination of antimicrobial drugs in rabbit plasma. Important aspects include plasma sample preparation, chromatographic optimization, calibration characteristics, selectivity, specificity, accuracy, precision, recovery, matrix

effects, carryover, dilution integrity, and stability. Previous literature has demonstrated the importance of systematic bioanalytical method development for pharmacokinetic, bioavailability, bioequivalence, and toxicokinetic studies (Tiwari & Tiwari, 2010; Nunsavathu & Thangabalan, 2024). Current regulatory recommendations, particularly ICH

M10, provide a standardized framework for demonstrating the reliability of bioanalytical procedures (ICH, 2022). Properly developed and validated RP-HPLC methods can therefore provide reliable analytical support for preclinical evaluation of antimicrobial drugs.

KEYWORDS: Antimicrobial drugs, rabbit plasma, bioanalytical validation, RP-HPLC, pharmacokinetics, sample preparation, chromatography.

1. INTRODUCTION

Antimicrobial drugs constitute an important group of therapeutic agents used in the management of infectious diseases. Determination of drug concentrations in biological matrices is essential for evaluating pharmacokinetic behavior, systemic exposure, bioavailability, and drug disposition. Reliable bioanalytical measurements are particularly important during preclinical pharmaceutical investigations because concentration–time data form the basis for calculating pharmacokinetic parameters and assessing drug exposure (Tiwari & Tiwari, 2010).

Bioanalytical analysis is more complex than conventional pharmaceutical assay because biological matrices contain numerous endogenous components capable of interfering with analyte detection. Plasma proteins, phospholipids, metabolites, and other endogenous substances may affect extraction efficiency and chromatographic response. Consequently, suitable sample preparation and chromatographic separation are necessary to obtain reliable results (Nunsavathu & Thangabalan, 2024).

RP-HPLC is an established analytical technique for the quantitative determination of pharmaceutical compounds in biological matrices. Its broad applicability, reproducibility, availability of different stationary phases, and compatibility with various detection systems make it particularly useful for bioanalytical applications. A properly developed method should provide adequate selectivity, sensitivity, precision, accuracy, and reproducibility (Tiwari & Tiwari, 2010).

2. Importance of Bioanalytical Method Development

Bioanalytical method development involves establishing analytical conditions capable of accurately identifying and quantifying an analyte in a biological matrix. The process generally includes selection of an appropriate stationary phase, optimization of the mobile phase, adjustment of flow rate and column temperature, selection of detection wavelength,

and development of an efficient sample-preparation procedure (Nunsavathu & Thangabalan, 2024).

The analytical method should provide adequate separation of the target compound from endogenous components and should generate a reproducible response over the intended concentration range. Method development is therefore closely associated with subsequent validation because the optimized conditions must demonstrate that the procedure is fit for its intended purpose (ICH, 2022).

Bioanalytical methods are particularly important in pharmacokinetic, bioavailability, bioequivalence, and toxicokinetic investigations. Reliable analytical measurements help ensure that differences observed in concentration–time profiles reflect actual differences in drug disposition rather than analytical variability (Tiwari & Tiwari, 2010).

3. Rabbit Plasma as a Biological Matrix

Rabbit plasma is used as a biological matrix in various preclinical pharmaceutical studies, including pharmacokinetic and bioavailability investigations. Blood samples collected from experimental animals can be processed to obtain plasma, which is subsequently analyzed for the target antimicrobial compound.

However, plasma is a complex biological matrix containing proteins, phospholipids, electrolytes, metabolites, and other endogenous substances. These constituents may interfere with chromatographic separation or influence detector response. Therefore, appropriate sample preparation is necessary before chromatographic injection (Tiwari & Tiwari, 2010).

The quality of the plasma sample also depends on appropriate collection, anticoagulation, processing, storage, and handling procedures. These factors should be controlled because inappropriate sample handling can contribute to analyte degradation or variability in measured concentrations. Regulatory guidance emphasizes appropriate control of sample handling and stability during bioanalytical studies (ICH, 2022).

4. Sample Preparation for Plasma Analysis

Sample preparation is one of the most important stages in bioanalytical method development because it influences analyte recovery, matrix effects, selectivity, and overall method performance. Common approaches include protein precipitation, liquid–liquid extraction, and solid-phase extraction (Nunsavathu & Thangabalan, 2024).

4.1 Protein Precipitation

Protein precipitation is a simple and relatively rapid technique in which an organic solvent is added to plasma to precipitate proteins. Methanol and acetonitrile are commonly used for this purpose. Following mixing and centrifugation, the supernatant containing the analyte can be collected for chromatographic analysis. The principal advantages of protein precipitation are simplicity, low solvent-processing requirements, and relatively rapid sample preparation (Tiwari & Tiwari, 2010).

4.2 Liquid–Liquid Extraction

Liquid–liquid extraction separates the analyte between an aqueous biological phase and an immiscible organic solvent. Optimization of solvent selection and pH can improve extraction efficiency. This technique may provide relatively clean extracts and can reduce the concentration of interfering endogenous constituents before chromatographic analysis (Nunsavathu & Thangabalan, 2024).

4.3 Solid-Phase Extraction

Solid-phase extraction involves retention of the analyte on a suitable sorbent followed by washing and elution. It can provide efficient removal of endogenous substances and may improve extract cleanliness. However, SPE generally requires greater optimization and may involve higher operational cost compared with simpler extraction procedures (Nunsavathu & Thangabalan, 2024).

5. RP-HPLC Method Development

RP-HPLC method development involves systematic optimization of chromatographic parameters to achieve satisfactory separation and quantitative performance. Reversed-phase C18 columns are frequently used for pharmaceutical bioanalysis because of their broad applicability to compounds with different physicochemical properties.

The mobile phase may contain aqueous buffer and organic solvents such as methanol or acetonitrile. The relative proportion of the organic component can significantly affect retention, resolution, peak shape, and analysis time. Flow rate and column temperature can also influence retention time and chromatographic efficiency.

Selection of the detection wavelength should be based on the absorption characteristics of the target compound and the requirement for adequate sensitivity. The optimized method should

produce a well-defined analyte peak with acceptable symmetry and sufficient separation from endogenous plasma components (Tiwari & Tiwari, 2010).

Recent reviews have emphasized that bioanalytical method development should be considered as an integrated process involving sampling, sample preparation, chromatographic separation, detection, data evaluation, and subsequent validation (Nunsavathu & Thangabalan, 2024).

6. Bioanalytical Method Validation

Validation is performed to demonstrate that the developed method is suitable for its intended analytical purpose. ICH M10 provides recommendations for validation of bioanalytical procedures and emphasizes parameters including selectivity, specificity, matrix effect, calibration curve and range, accuracy, precision, carryover, dilution integrity, recovery, and stability (ICH, 2022).

6.1 Selectivity

Selectivity refers to the ability of the analytical procedure to distinguish the analyte from endogenous matrix components and other substances present in the sample. Blank plasma samples from multiple sources are generally examined to establish that endogenous components do not produce significant interference at the analyte retention time (ICH, 2022).

6.2 Specificity

Specificity is concerned with demonstrating that the analytical response originates from the intended analyte rather than from interfering substances. Chromatographic separation and appropriate sample analysis are used to establish the specificity of the method (Tiwari & Tiwari, 2010).

6.3 Calibration Curve and Linearity

The calibration curve establishes the mathematical relationship between analyte concentration and measured analytical response. Multiple calibration levels covering the intended range are analyzed, and the resulting data are evaluated using an appropriate calibration model. ICH M10 identifies calibration curve and range as important components of chromatographic bioanalytical validation (ICH, 2022).

6.4 Accuracy

Accuracy describes the closeness of the measured concentration to the nominal concentration. It is generally evaluated using quality-control samples at different concentration levels distributed across the validated analytical range. The acceptance criteria should be established according to the applicable bioanalytical validation guideline (ICH, 2022).

6.5 Precision

Precision indicates the closeness of repeated measurements and is generally expressed using percentage coefficient of variation (%CV) or percentage relative standard deviation (%RSD). Both within-run and between-run precision are considered during bioanalytical validation (Tiwari & Tiwari, 2010; ICH, 2022).

6.6 Recovery

Recovery represents the amount of analyte obtained after extraction from the biological matrix relative to the amount present before extraction. Consistent recovery is important for ensuring reproducible quantitative measurements. The absolute magnitude of recovery may vary according to the extraction procedure, provided that the process is consistent and reproducible (ICH, 2022).

6.7 Matrix Effect

Matrix effects occur when endogenous components of plasma alter the analytical response of the target compound. They may result in ion enhancement or suppression depending on the analytical technique and detection system. Evaluation of matrix effects is therefore an important component of bioanalytical method validation (ICH, 2022; Tiwari & Tiwari, 2010).

6.8 Carryover

Carryover occurs when residual analyte from a previous injection affects the response of a subsequent sample. It can be investigated by injecting blank samples following high-concentration samples. Appropriate washing procedures and optimized chromatographic conditions should minimize carryover (ICH, 2022).

6.9 Dilution Integrity

Dilution integrity demonstrates that samples containing concentrations above the validated range can be diluted with an appropriate matrix or diluent without adversely affecting accuracy and precision. This parameter is particularly relevant when study samples may exceed the upper limit of quantification (ICH, 2022).

6.10 Stability

Stability evaluation determines whether the analyte remains unchanged during the different stages of sample handling and analysis. Important studies may include bench-top stability, freeze–thaw stability, long-term storage stability, processed-sample stability, stock-solution stability, and working-solution stability. Stability studies should reflect the actual conditions under which samples and solutions are handled during the study (ICH, 2022).

7. Literature Review

Early literature established that bioanalytical method validation is essential for obtaining reliable quantitative information from biological matrices. Tiwari and Tiwari (2010) described the importance of sample preparation, selectivity, specificity, sensitivity, calibration range, accuracy, precision, recovery, stability, robustness, and related parameters in chromatographic bioanalysis. They further emphasized the importance of validated methods for pharmacokinetic, toxicokinetic, bioavailability, and bioequivalence investigations.

Nunsavathu and Thangabalan (2024) reviewed RP-HPLC-based bioanalytical method development and highlighted the importance of sample preparation, chromatographic separation, detection, and validation. Their review discussed commonly used extraction approaches such as protein precipitation, liquid–liquid extraction, and solid-phase extraction and emphasized the role of bioanalytical validation in pharmacokinetic, bioavailability, bioequivalence, and toxicokinetic studies.

Regulatory expectations have subsequently become more harmonized through ICH M10. The guideline, adopted in 2022 and effective from January 2023, provides recommendations for validation of bioanalytical assays and analysis of study samples. It specifically addresses chromatographic validation characteristics such as selectivity, specificity, matrix effect, calibration curve and range, accuracy, precision, carryover, dilution integrity, recovery, and stability (ICH, 2022).

The U.S. Food and Drug Administration's *Bioanalytical Method Validation Guidance for Industry* also provides recommendations for development, validation, and application of bioanalytical methods. The guidance covers chromatographic assays used for quantitative determination of drugs and metabolites in biological matrices and notes that its principles can

also inform nonclinical studies requiring concentration measurements (FDA, 2018).

Collectively, the literature demonstrates that successful bioanalytical method development requires integration of sample preparation, chromatographic separation, detection, and systematic validation. For antimicrobial drugs in rabbit plasma, these principles are particularly relevant because the biological matrix can introduce analytical variability if endogenous components are not adequately controlled. Therefore, development of a selective, precise, accurate, and reproducible RP-HPLC procedure can provide a suitable analytical foundation for preclinical pharmacokinetic investigations.

8. Application in Pharmacokinetic Studies

Validated bioanalytical methods are fundamental to pharmacokinetic studies because plasma concentration measurements are used to construct concentration–time profiles. These profiles can subsequently be used to estimate pharmacokinetic parameters such as maximum plasma concentration, time to maximum concentration, area under the concentration–time curve, elimination half-life, clearance, and volume of distribution.

The reliability of these pharmacokinetic parameters depends partly on the quality of the underlying analytical data. Consequently, systematic validation of the bioanalytical procedure is necessary before it is applied to study samples (Tiwari & Tiwari, 2010; ICH, 2022).

9. Regulatory Perspective

The ICH M10 guideline represents the current harmonized framework for bioanalytical method validation and study sample analysis. It was adopted in July 2022 and became legally effective in the European Union on January 21, 2023 (ICH, 2022).

The FDA guidance issued in 2018 similarly provides recommendations for bioanalytical methods used in pharmacokinetic, toxicokinetic, bioavailability, and bioequivalence studies. It covers chromatographic assays for biological matrices including plasma and provides recommendations concerning method development, validation, and application (FDA, 2018).

Thus, development of an RP-HPLC method for antimicrobial drugs in rabbit plasma should be undertaken with consideration of current regulatory expectations and the specific requirements of the intended preclinical application.

10. Research Gap and Rationale

Although RP-HPLC has been extensively applied to bioanalytical investigations, differences in physicochemical properties, extraction behavior, plasma matrix composition, and detector response can necessitate optimization of analytical conditions for individual compounds or compound groups. Existing literature also demonstrates continued interest in improving sample preparation, reducing analysis time, minimizing solvent consumption, and enhancing method reproducibility (Nunsavathu & Thangabalan, 2024).

Therefore, development and validation of an RP-HPLC method for the estimation of antimicrobial drugs in rabbit plasma can provide a useful analytical approach for preclinical pharmacokinetic and bioavailability studies. Such a method should emphasize adequate selectivity, sensitivity, accuracy, precision, recovery, stability, and reproducibility in accordance with established bioanalytical principles (ICH, 2022).

11. CONCLUSION

Bioanalytical validation is a fundamental requirement for obtaining reliable quantitative data from biological matrices. The literature demonstrates that RP-HPLC provides a practical and versatile approach for the estimation of antimicrobial drugs in rabbit plasma when suitable sample preparation and chromatographic conditions are established. Systematic evaluation of selectivity, specificity, calibration performance, accuracy, precision, recovery, matrix effects, carryover, dilution integrity, and stability is essential for demonstrating method reliability (Tiwari & Tiwari, 2010; ICH, 2022). Current regulatory recommendations from ICH M10 and FDA provide a structured framework for validating chromatographic bioanalytical methods (FDA, 2018; ICH, 2022). Consequently, a properly optimized and validated RP-HPLC procedure can serve as a dependable analytical tool for preclinical pharmacokinetic and bioavailability studies involving antimicrobial drugs.

12. REFERENCES

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). *ICH guideline M10 on bioanalytical method validation and study sample analysis*. European Medicines Agency.
2. Nunsavathu, S. N., & Thangabalan, B. A RP-HPLC approach to bioanalytical method development and validation: A review. *Asian Journal of Pharmaceutical Analysis*, 2024; 14(1): 47–50. <https://doi.org/10.52711/2231-5675.2024.00009>
3. Tiwari, G., & Tiwari, R. Bioanalytical method validation: An updated review. *Pharmaceutical Methods*, 2010; 1(1): 25–38. <https://doi.org/10.4103/2229-4708.72226>

4. U.S. Food and Drug Administration. (2018). *Bioanalytical method validation: Guidance for industry*. U.S. Department of Health and Human Services.
5. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A., Layloff, T., Viswanathan, C. T., Cook, C. E., McDowall, R. D., Pittman, K. A., & Spector, S. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. *Journal of Pharmaceutical Sciences*, 1992; 81(3): 309–312.
6. Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., Tonelli, A., Viswanathan, C. T., & Yacobi, A. Bioanalytical method validation—A revisit with a decade of progress. *Pharmaceutical Research*, 2000; 17: 1551–1557.
7. Viswanathan, C. T., Bansal, S., Booth, B., DeStefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., & Weiner, R. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. *Pharmaceutical Research*, 2007; 24: 1962–1973.
8. Bansal, S., & DeStefano, A. Key elements of bioanalytical method validation for small molecules. *The AAPS Journal*, 2007; 9: E109–E114.
9. Wieling, J. LC-MS-MS: An introduction to bioanalytical applications. *Journal of Chromatography B*, 2002; 775: 1–13.
10. Matuszewski, B. K., Constanzer, M. L., & Chavez-Eng, C. M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. *Analytical Chemistry*, 2003; 75: 3019–3030.
11. Matuszewski, B. K., Constanzer, M. L., & Chavez-Eng, C. M. A systematic approach to the assessment of matrix effects in quantitative bioanalytical methods. *Journal of Pharmaceutical and Biomedical Analysis*, 2003; 31: 1379–1390.
12. Kadian, N., Raju, K. S. R., Rashid, M., Malik, M. Y., Tiwari, A. K., & Chaudhary, A. A review on bioanalytical method development and validation. *International Journal of Pharmaceutical Sciences and Research*, 2016; 7: 1–12.
13. Hartmann, C., Smeyers-Verbeke, J., Massart, D. L., & McDowall, R. D. Validation of bioanalytical chromatographic methods. *Journal of Pharmaceutical and Biomedical Analysis*, 1995; 13: 1383–1394.
14. Karnes, H. T., & March, C. Precision, accuracy, and data acceptance criteria in bioanalytical method validation. *Pharmaceutical Research*, 1991; 8: 421–426.
15. Krouwer, J. S., & Rabinowitz, R. How to improve estimates of precision in clinical methods. *Clinical Chemistry*, 1984; 30: 290–292.

16. Thompson, M., Ellison, S. L. R., & Wood, R. Harmonized guidelines for single-laboratory validation of methods of analysis. *Pure and Applied Chemistry*, 2002; 74: 835–855.
17. Taverniers, I., De Loose, M., & Van Bockstaele, E. Trends in quality in the analytical laboratory. II. Analytical method validation and quality assurance. *Trends in Analytical Chemistry*, 2004; 23: 535–552.
18. Ermer, J. Validation in pharmaceutical analysis. Part I: An integrated approach. *Journal of Pharmaceutical and Biomedical Analysis*, 2001; 24: 755–767.
19. Ermer, J., & Miller, J. H. M. (2005). *Method validation in pharmaceutical analysis: A guide to best practice*. Wiley-VCH.